Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRANASDAQ:ATYRNASDAQ:LFCRNASDAQ:MRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$7.25-7.3%$6.61$5.01▼$18.71$43.22M0.32122,983 shs37,665 shsATYRAtyr PHARMA$3.58-0.6%$3.29$1.42▼$4.66$318.12M0.79900,482 shs746,125 shsLFCRLifecore Biomedical$7.02-3.7%$6.32$3.68▼$7.99$269.91M0.65231,959 shs300,894 shsMRSNMersana Therapeutics$0.37-8.2%$0.40$0.26▼$3.63$45.49M1.322.50 million shs1.77 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-7.29%-2.29%+29.70%-22.04%-56.72%ATYRAtyr PHARMA-0.56%+9.48%+36.64%-6.04%+357,999,900.00%LFCRLifecore Biomedical-3.70%+8.84%+32.70%+18.18%+9.86%MRSNMersana Therapeutics-8.22%-4.90%+20.50%-39.67%-89.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.5436 of 5 stars3.32.00.04.70.02.50.6ATYRAtyr PHARMA2.6899 of 5 stars3.61.00.00.03.23.30.6LFCRLifecore Biomedical1.3103 of 5 stars2.21.00.00.02.33.30.6MRSNMersana Therapeutics3.8142 of 5 stars3.52.00.04.12.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.57Moderate Buy$17.75144.83% UpsideATYRAtyr PHARMA 3.14Buy$18.60419.55% UpsideLFCRLifecore Biomedical 2.33Hold$8.0013.96% UpsideMRSNMersana Therapeutics 3.00Buy$4.00995.89% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, LFCR, ATYR, and MRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.003/11/2025ATRAAtara BiotherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/3/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.002/18/2025ATYRAtyr PHARMALeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/18/2025ATYRAtyr PHARMALeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$16.002/6/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.34N/AN/A($24.34) per share-0.30ATYRAtyr PHARMA$235K1,353.68N/AN/A$1.54 per share2.32LFCRLifecore Biomedical$130.31M1.99N/AN/A$0.37 per share18.97MRSNMersana Therapeutics$40.50M1.12N/AN/A$0.31 per share1.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$276.13M-$12.97N/AN/AN/A-132.58%N/A-90.16%5/8/2025 (Estimated)ATYRAtyr PHARMA-$50.39M-$0.87N/AN/AN/AN/A-79.44%-59.16%N/ALFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-12.52%-315.23%-12.74%N/AMRSNMersana Therapeutics-$171.67M-$0.56N/AN/AN/A-214.20%-401.37%-38.61%5/8/2025 (Estimated)Latest ATRA, LFCR, ATYR, and MRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ATRAAtara Biotherapeutics-$3.07N/AN/AN/A$4.30 millionN/A5/8/2025Q1 2025MRSNMersana Therapeutics-$0.21N/AN/AN/A$6.05 millionN/A4/3/2025Q3 2025LFCRLifecore Biomedical-$0.14-$0.19-$0.05-$0.47$33.23 million$35.15 million3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A3/7/2025Q4 2024ATRAAtara Biotherapeutics-$3.82-$1.19+$2.63-$1.19$20.58 million$32.75 million3/3/2025Q4 2024MRSNMersana Therapeutics-$0.16-$0.11+$0.05-$0.11$7.71 million$16.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AATYRAtyr PHARMAN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.590.50ATYRAtyr PHARMA0.025.415.41LFCRLifecore Biomedical9.212.321.21MRSNMersana Therapeutics13.352.352.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%ATYRAtyr PHARMA61.72%LFCRLifecore Biomedical83.36%MRSNMersana Therapeutics93.92%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics3.70%ATYRAtyr PHARMA3.70%LFCRLifecore Biomedical32.20%MRSNMersana Therapeutics11.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3305.96 million5.55 millionOptionableATYRAtyr PHARMA5388.86 million80.84 millionOptionableLFCRLifecore Biomedical69037.03 million26.58 millionOptionableMRSNMersana Therapeutics150124.63 million108.96 millionOptionableATRA, LFCR, ATYR, and MRSN HeadlinesRecent News About These CompaniesMersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast CancerMay 6 at 7:00 AM | globenewswire.com4,250,000 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Novo Holdings A SMay 3 at 8:09 AM | marketbeat.comMersana Therapeutics (MRSN) Expected to Announce Earnings on ThursdayMay 3 at 2:46 AM | marketbeat.comWhy Mersana Therapeutics, Inc.’s (MRSN) Stock Is Down 8.13%May 2, 2025 | aaii.comMersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual MeetingApril 23, 2025 | globenewswire.comMersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual CongressApril 1, 2025 | globenewswire.comMersana at Leerink Global Healthcare Conference: Strategic ADC InsightsMarch 14, 2025 | investing.comEarnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their EstimatesMarch 6, 2025 | finance.yahoo.comIndustry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue ForecastsMarch 6, 2025 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | insidermonkey.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | finanznachrichten.deMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | finance.yahoo.comMersana Therapeutics reports Q4 EPS (11c), consensus (17c)March 3, 2025 | markets.businessinsider.comMersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue EstimatesMarch 3, 2025 | zacks.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | globenewswire.comMersana Therapeutics faces Nasdaq delisting over share priceMarch 2, 2025 | uk.investing.comMersana Therapeutics Q4 2024 Earnings PreviewFebruary 28, 2025 | msn.comMersana Therapeutics to Present at Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comMersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025February 24, 2025 | globenewswire.comMersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comWilliam Blair starts Mersana stock with Outperform ratingFebruary 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRA, LFCR, ATYR, and MRSN Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$7.25 -0.57 (-7.29%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$8.23 +0.98 (+13.52%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Atyr PHARMA NASDAQ:ATYR$3.58 -0.02 (-0.56%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$3.57 -0.01 (-0.39%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Lifecore Biomedical NASDAQ:LFCR$7.02 -0.27 (-3.70%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$7.04 +0.02 (+0.28%) As of 07:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Mersana Therapeutics NASDAQ:MRSN$0.36 -0.03 (-8.22%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$0.35 -0.02 (-4.66%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Monster Beverage Stock: Short Report Risks vs Upside Potential Onsemi Stock Confirms Bottom, But What’s the Upside? 3 Reasons Tesla Should Be a $300 Stock by June Qualcomm: Analyst Opinions Split, But Upside Potential Remains Amazon: Why The Great Comeback Rally Could Be About to Begin Is Reddit Stock a Buy, Sell, or Hold After Earnings Release? MarketBeat Week in Review – 04/28 - 05/02 ExxonMobil: Production Offset Prices, Capital Return Safe in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
